Beta Bionics (NASDAQ:BBNX) Insider Mark Hopman Sells 834 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 834 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $12.36, for a total value of $10,308.24. Following the completion of the transaction, the insider directly owned 139,486 shares of the company’s stock, valued at approximately $1,724,046.96. The trade was a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Beta Bionics Stock Performance

Shares of BBNX opened at $11.57 on Wednesday. The firm has a market capitalization of $513.48 million, a PE ratio of -5.93 and a beta of 5.60. The stock has a 50 day simple moving average of $18.74 and a 200 day simple moving average of $22.43. Beta Bionics, Inc. has a 52-week low of $8.89 and a 52-week high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.12. The company had revenue of $32.12 million during the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Key Headlines Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Neutral Sentiment: Short‑interest data appears unreliable or reporting‑error driven (entries show “0 shares”/NaN and 0.0 days to cover), so there’s no clear signal from short sellers in these reports — treat short‑interest changes as inconclusive for now.
• Negative Sentiment: Multiple insiders sold shares in early March (CFO Stephen Feider sold 1,428 shares at ~$12.36; other executives also sold small blocks), prompting the narrative of a wave of executive exits that can pressure the stock. These trades were disclosed in SEC Form 4 filings and covered in a TipRanks piece highlighting the coordinated sales. Beta Bionics Insiders Quietly Cash Out CFO Form 4
• Negative Sentiment: A securities‑litigation firm (Faruqi & Faruqi, LLP) issued a shareholder reminder/investigation notice encouraging investors who suffered losses to contact them — this increases legal and reputational risk and can weigh on sentiment and share price until resolved. Faruqi & Faruqi Shareholder Reminder

Wall Street Analyst Weigh In

Several brokerages recently commented on BBNX. Stifel Nicolaus reduced their target price on shares of Beta Bionics from $25.00 to $22.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. UBS Group upgraded shares of Beta Bionics to a “strong-buy” rating in a research note on Monday, February 9th. Lake Street Capital set a $20.00 price objective on Beta Bionics in a report on Wednesday, February 18th. Robert W. Baird dropped their target price on Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Finally, Wall Street Zen downgraded Beta Bionics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $23.20.

Institutional Trading of Beta Bionics

A number of hedge funds have recently made changes to their positions in the business. GPS Wealth Strategies Group LLC increased its holdings in shares of Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after acquiring an additional 450 shares during the last quarter. Strs Ohio bought a new stake in shares of Beta Bionics during the first quarter worth approximately $29,000. EverSource Wealth Advisors LLC increased its stake in shares of Beta Bionics by 203.6% during the third quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after purchasing an additional 1,594 shares during the period. Summit Securities Group LLC acquired a new stake in Beta Bionics during the 4th quarter worth approximately $52,000. Finally, CWM LLC acquired a new position in Beta Bionics in the 2nd quarter valued at $58,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.